ID	start_index	end_index	token	lemma	POS
1	24	27	The	the	DT
2	28	35	problem	problem	NN
3	44	49	Three	three	CD
4	50	59	published	publish	VBN
6	62	63	1	1	CD
7	64	65	2	2	CD
8	66	67	3	3	CD
10	70	73	and	and	CC
11	74	77	one	one	CD
12	78	86	recently	recently	RB
13	87	96	presented	present	VBN
15	99	100	4	4	CD
17	111	121	randomized	randomize	JJ
18	122	140	placebo-controlled	placebo-controll	JJ
19	141	149	clinical	clinical	JJ
20	150	155	trial	trial	NN
21	156	160	have	have	VBP
22	169	182	unequivocally	unequivocally	RB
23	183	195	demonstrated	demonstrate	VBN
24	196	200	that	that	IN
25	201	202	3	3	CD
27	203	211	Hydroxy-	hydroxy-	NNP
28	211	212	3	3	CD
30	213	227	methylgluatryl	methylgluatryl	NN
31	236	244	coenzyme	coenzyme	NN
34	248	251	HMG	hmg	NNP
35	252	255	CoA	coa	NNP
37	257	266	reductase	reductase	NN
38	267	277	inhibitors	inhibitor	NNS
40	279	286	statins	statin	NNS
42	288	294	reduce	reduce	VB
43	303	306	the	the	DT
44	307	316	morbidity	morbidity	NN
45	317	320	and	and	CC
46	321	330	mortality	mortality	NN
47	331	341	associated	associate	VBN
48	342	346	with	with	IN
49	347	355	coronary	coronary	JJ
50	364	371	disease	disease	NN
52	373	378	These	these	DT
53	379	385	trials	trial	NNS
54	386	391	found	find	VBD
55	392	396	that	that	IN
56	397	401	when	when	WRB
57	402	410	compared	compare	VBN
58	411	415	with	with	IN
59	424	431	placebo	placebo	NN
61	433	440	statins	statin	NNS
62	441	454	significantly	significantly	RB
63	455	462	reduced	reduce	VBD
64	463	466	the	the	DT
65	467	476	incidence	incidence	NN
66	477	479	of	of	IN
67	488	493	death	death	NN
69	495	505	myocardial	myocardial	NN
70	506	516	infarction	infarction	NN
72	518	526	unstable	unstable	JJ
73	527	533	angina	angina	NN
75	535	547	percutaneous	percutaneous	JJ
76	556	559	and	and	CC
77	560	568	surgical	surgical	JJ
78	569	577	coronary	coronary	JJ
79	578	595	revascularization	revascularization	NN
81	597	600	and	and	CC
82	601	607	stroke	stroke	NN
83	608	610	in	in	IN
84	619	626	persons	person	NNS
85	627	631	with	with	IN
86	641	647	stable	stable	JJ
87	648	656	coronary	coronary	JJ
88	657	664	disease	disease	NN
90	666	673	Because	because	IN
91	682	690	patients	patient	NNS
92	691	694	who	who	WP
93	695	698	had	have	VBD
94	699	710	experienced	experience	VBN
95	711	713	an	an	DT
96	714	719	acute	acute	JJ
97	720	728	coronary	coronary	JJ
98	729	737	syndrome	syndrome	NN
99	746	752	within	within	IN
100	753	758	three	three	CD
101	759	761	to	to	TO
102	762	765	six	six	CD
103	766	772	months	month	NNS
104	773	775	of	of	IN
105	776	786	enrollment	enrollment	NN
106	787	791	were	be	VBD
107	792	800	excluded	exclude	VBN
109	810	815	these	these	DT
110	816	822	trials	trial	NNS
111	823	826	did	do	VBD
112	827	830	not	not	RB
113	831	837	assess	assess	VB
114	838	841	the	the	DT
115	842	848	effect	effect	NN
116	849	851	of	of	IN
117	852	866	lipid-lowering	lipid-lower	JJ
118	875	882	therapy	therapy	NN
119	883	885	on	on	IN
120	886	893	adverse	adverse	JJ
121	894	908	cardiovascular	cardiovascular	JJ
122	909	915	events	event	NNS
123	916	918	in	in	IN
124	919	924	those	those	DT
125	925	929	with	with	IN
126	938	946	recently	recently	RB
127	956	964	unstable	unstable	JJ
128	965	973	coronary	coronary	JJ
129	974	981	disease	disease	NN
131	983	990	Whether	whether	IN
132	999	1013	lipid-lowering	lipid-lower	JJ
133	1014	1021	therapy	therapy	NN
134	1022	1027	would	would	MD
135	1028	1035	provide	provide	VB
136	1036	1047	incremental	incremental	JJ
137	1048	1055	benefit	benefit	NN
138	1056	1058	if	if	IN
139	1067	1076	initiated	initiate	VBN
140	1077	1088	immediately	immediately	RB
141	1089	1098	following	follow	VBG
142	1099	1101	an	an	DT
143	1102	1107	acute	acute	JJ
144	1108	1116	coronary	coronary	JJ
145	1117	1125	syndrome	syndrome	NN
146	1134	1136	is	be	VBZ
147	1137	1139	an	an	DT
148	1140	1149	important	important	JJ
149	1150	1155	issue	issue	NN
150	1156	1158	as	as	IN
151	1159	1162	the	the	DT
152	1163	1167	risk	risk	NN
153	1168	1170	of	of	IN
154	1171	1172	a	a	DT
155	1173	1182	recurrent	recurrent	JJ
156	1183	1190	adverse	adverse	JJ
157	1199	1206	cardiac	cardiac	JJ
158	1207	1213	events	event	NNS
159	1214	1216	is	be	VBZ
160	1217	1221	much	much	RB
161	1222	1229	greater	greater	JJR
162	1230	1232	in	in	IN
163	1233	1241	patients	patient	NNS
164	1242	1246	with	with	IN
165	1247	1255	unstable	unstable	JJ
166	1264	1272	coronary	coronary	JJ
167	1273	1280	disease	disease	NN
168	1281	1285	than	than	IN
169	1286	1288	in	in	IN
170	1289	1292	the	the	DT
171	1293	1299	stable	stable	JJ
172	1300	1307	setting	set	NN
174	1309	1312	The	the	DT
175	1313	1323	Myocardial	myocardial	NNP
176	1332	1340	Ischemia	ischemium	NNP
177	1341	1350	Reduction	reduction	NNP
178	1351	1355	with	with	IN
179	1356	1366	Aggressive	aggressive	NNP
180	1367	1378	Cholesterol	cholesterol	NNP
181	1379	1387	Lowering	lower	NNP
183	1397	1403	MIRACL	miracl	NNP
185	1405	1410	trial	trial	NN
186	1411	1414	set	set	VBN
187	1415	1418	out	out	IN
188	1419	1421	to	to	TO
189	1422	1428	answer	answer	VB
190	1429	1433	this	this	DT
191	1434	1442	question	question	NN
193	1466	1469	The	the	DT
194	1470	1476	answer	answer	NN
196	1486	1492	MIRACL	miracl	NNP
197	1493	1501	enrolled	enroll	VBD
198	1502	1507	3,086	3,086	CD
199	1508	1516	patients	patient	NNS
200	1517	1523	within	within	IN
201	1524	1526	24	24	CD
203	1527	1529	96	96	CD
204	1530	1535	hours	hour	NNS
206	1537	1541	mean	mean	VB
207	1550	1552	63	63	CD
208	1553	1558	hours	hour	NNS
210	1560	1562	of	of	IN
211	1563	1572	admission	admission	NN
212	1573	1576	for	for	IN
213	1577	1585	unstable	unstable	JJ
214	1586	1592	angina	angina	NN
215	1593	1595	or	or	CC
216	1596	1597	a	a	DT
217	1598	1602	non-	non-	NN
218	1602	1604	Q-	q-	NNP
219	1604	1608	wave	wave	NN
220	1617	1627	myocardial	myocardial	NN
221	1628	1638	infarction	infarction	NN
222	1639	1642	and	and	CC
223	1643	1653	randomized	randomize	JJ
224	1654	1658	them	them	PRP
225	1659	1661	to	to	TO
226	1662	1664	16	16	CD
227	1665	1670	weeks	week	NNS
228	1671	1673	of	of	IN
229	1682	1694	atorvastatin	atorvastatin	NN
230	1695	1697	80	80	CD
231	1698	1700	mg	mg	NN
232	1701	1703	or	or	CC
233	1704	1711	placebo	placebo	NN
234	1712	1716	once	once	RB
235	1717	1722	daily	daily	JJ
237	1725	1726	5	5	CD
240	1731	1734	The	the	DT
241	1735	1740	major	major	JJ
242	1749	1758	exclusion	exclusion	NN
243	1759	1767	criteria	criterion	NNS
244	1768	1772	were	be	VBD
246	1774	1779	total	total	JJ
247	1780	1791	cholesterol	cholesterol	NN
248	1792	1797	level	level	NN
249	1798	1805	greater	greater	JJR
250	1814	1818	than	than	IN
251	1819	1822	270	270	CD
252	1823	1825	mg	mg	NN
254	1826	1828	dL	dl	NN
256	1830	1832	Q-	q-	NNP
257	1832	1836	wave	wave	NN
258	1837	1847	myocardial	myocardial	NN
259	1848	1858	infarction	infarction	NN
260	1859	1861	on	on	IN
261	1862	1871	admission	admission	NN
262	1880	1882	or	or	CC
263	1883	1889	during	during	IN
264	1890	1893	the	the	DT
265	1894	1902	previous	previous	JJ
266	1903	1908	month	month	NN
268	1910	1913	and	and	CC
270	1915	1923	coronary	coronary	JJ
271	1932	1949	revascularization	revascularization	NN
272	1950	1952	in	in	IN
273	1953	1956	the	the	DT
274	1957	1963	months	month	NNS
275	1964	1970	before	before	IN
276	1971	1980	admission	admission	NN
278	1982	1988	during	during	IN
279	1997	2000	the	the	DT
280	2001	2006	index	index	NN
281	2007	2022	hospitalization	hospitalization	NN
282	2023	2025	or	or	CC
283	2026	2037	anticipated	anticipate	VBN
284	2038	2047	following	follow	VBG
285	2048	2056	hospital	hospital	NN
286	2065	2074	discharge	discharge	NN
288	2076	2079	The	the	DT
289	2080	2087	primary	primary	JJ
290	2088	2096	efficacy	efficacy	NN
291	2097	2105	endpoint	endpoint	NN
292	2106	2109	was	be	VBD
293	2110	2111	a	a	DT
294	2112	2121	composite	composite	NN
295	2122	2124	of	of	IN
296	2133	2138	death	death	NN
298	2140	2149	non-fatal	non-fatal	JJ
299	2150	2160	myocardial	myocardial	NN
300	2161	2171	infarction	infarction	NN
302	2173	2185	resuscitated	resuscitate	JJ
303	2186	2192	sudden	sudden	JJ
304	2201	2208	cardiac	cardiac	JJ
305	2209	2214	death	death	NN
306	2215	2217	or	or	CC
307	2218	2226	emergent	emergent	NN
308	2227	2244	rehospitalization	rehospitalization	NN
309	2245	2248	for	for	IN
310	2249	2258	worsening	worsen	VBG
311	2267	2278	symptomatic	symptomatic	JJ
312	2279	2289	myocardial	myocardial	NN
313	2290	2298	ischemia	ischemium	NN
315	2300	2309	Secondary	secondary	JJ
316	2310	2319	endpoints	endpoint	NNS
317	2328	2336	included	include	VBD
318	2337	2343	stroke	stroke	NN
320	2345	2354	worsening	worsen	VBG
321	2355	2360	heart	heart	NN
322	2361	2368	failure	failure	NN
324	2370	2374	need	need	NN
325	2375	2378	for	for	IN
326	2379	2387	coronary	coronary	JJ
327	2396	2413	revascularization	revascularization	NN
328	2414	2417	and	and	CC
329	2418	2424	change	change	NN
330	2425	2427	in	in	IN
331	2428	2433	lipid	lipid	NN
332	2434	2440	levels	level	NNS
333	2441	2451	throughout	throughout	IN
334	2452	2455	the	the	DT
335	2464	2469	study	study	NN
337	2471	2473	On	on	IN
338	2474	2481	average	average	JJ
340	2483	2491	patients	patient	NNS
341	2492	2496	were	be	VBD
342	2497	2499	65	65	CD
343	2500	2505	years	year	NNS
344	2506	2508	of	of	IN
345	2509	2512	age	age	NN
347	2522	2535	approximately	approximately	RB
348	2536	2538	65	65	CD
350	2540	2544	were	be	VBD
351	2545	2548	men	man	NNS
353	2550	2552	86	86	CD
355	2554	2563	Caucasian	caucasian	NNP
356	2564	2567	and	and	CC
357	2568	2571	the	the	DT
358	2572	2576	mean	mean	JJ
359	2585	2593	baseline	baseline	NN
360	2594	2597	low	low	JJ
361	2598	2605	density	density	NN
362	2606	2617	lipoprotein	lipoprotein	NN
364	2619	2622	LDL	ldl	NNP
366	2624	2635	cholesterol	cholesterol	NN
367	2636	2641	level	level	NN
368	2650	2653	was	be	VBD
369	2654	2657	124	124	CD
370	2658	2660	mg	mg	NN
372	2661	2663	dL	dl	NN
374	2665	2677	Atorvastatin	atorvastatin	NNP
375	2678	2687	treatment	treatment	NN
376	2688	2691	was	be	VBD
377	2692	2702	associated	associate	VBN
378	2703	2707	with	with	IN
379	2708	2709	a	a	DT
380	2718	2721	2.6	2.6	CD
382	2723	2731	absolute	absolute	JJ
383	2732	2741	reduction	reduction	NN
384	2742	2744	in	in	IN
385	2745	2748	the	the	DT
386	2749	2753	risk	risk	NN
387	2754	2756	of	of	IN
388	2757	2760	the	the	DT
389	2761	2768	primary	primary	JJ
390	2769	2777	endpoint	endpoint	NN
392	2787	2791	14.8	14.8	CD
394	2793	2796	vs.	vs.	NN
395	2797	2801	17.4	17.4	CD
398	2804	2806	RR	rr	NNP
399	2807	2815	relative	relative	JJ
400	2816	2820	risk	risk	NN
402	2822	2824	RR	rr	NNP
404	2826	2830	0.84	0.84	CD
406	2832	2834	95	95	CD
408	2844	2854	confidence	confidence	NN
409	2855	2863	interval	interval	NN
411	2865	2867	CI	cus	NNP
413	2869	2873	0.70	0.70	CD
415	2874	2878	1.00	1.00	CD
419	2884	2889	0.048	0.048	CD
422	2892	2896	This	this	DT
423	2905	2914	reduction	reduction	NN
424	2915	2918	was	be	VBD
425	2919	2928	primarily	primarily	RB
426	2929	2935	driven	drive	VBN
427	2936	2938	by	by	IN
428	2939	2942	the	the	DT
429	2943	2946	2.2	2.2	CD
431	2948	2956	absolute	absolute	JJ
432	2965	2974	reduction	reduction	NN
433	2975	2977	in	in	IN
434	2978	2987	incidence	incidence	NN
435	2988	2990	of	of	IN
436	2991	2999	emergent	emergent	NN
437	3000	3017	rehospitalization	rehospitalization	NN
438	3018	3021	for	for	IN
439	3030	3041	symptomatic	symptomatic	JJ
440	3042	3052	myocardial	myocardial	NN
441	3053	3061	ischemia	ischemium	NN
443	3063	3066	6.2	6.2	CD
445	3068	3071	vs.	vs.	NN
446	3072	3075	8.4	8.4	CD
449	3078	3080	RR	rr	NNP
450	3081	3085	0.74	0.74	CD
452	3095	3097	95	95	CD
454	3099	3101	CI	cus	NNP
455	3102	3106	0.57	0.57	CD
457	3107	3111	0.95	0.95	CD
461	3117	3121	0.02	0.02	CD
464	3124	3127	The	the	DT
465	3128	3132	risk	risk	NN
466	3133	3135	of	of	IN
467	3136	3141	death	death	NN
469	3143	3151	nonfatal	nonfatal	NN
470	3160	3170	myocardial	myocardial	NN
471	3171	3181	infarction	infarction	NN
472	3182	3185	and	and	CC
473	3186	3198	resuscitated	resuscitate	JJ
474	3199	3205	sudden	sudden	JJ
475	3206	3213	cardiac	cardiac	JJ
476	3214	3219	death	death	NN
477	3228	3232	were	be	VBD
478	3233	3237	each	each	DT
479	3238	3240	no	no	DT
480	3241	3250	different	different	JJ
481	3251	3258	between	between	IN
482	3259	3262	the	the	DT
483	3263	3266	two	two	CD
484	3267	3273	groups	group	NNS
486	3275	3280	While	while	IN
487	3281	3286	there	there	EX
488	3295	3299	were	be	VBD
489	3300	3302	no	no	DT
490	3303	3314	significant	significant	JJ
491	3315	3326	differences	difference	NNS
492	3327	3329	in	in	IN
493	3330	3333	the	the	DT
494	3334	3343	incidence	incidence	NN
495	3344	3346	of	of	IN
496	3355	3364	worsening	worsen	VBG
497	3365	3370	heart	heart	NN
498	3371	3378	failure	failure	NN
499	3379	3381	or	or	CC
500	3382	3386	need	need	NN
501	3387	3390	for	for	IN
502	3391	3399	coronary	coronary	JJ
503	3408	3425	revascularization	revascularization	NN
505	3427	3439	atorvastatin	atorvastatin	NN
506	3440	3443	did	do	VBD
507	3444	3450	reduce	reduce	VB
508	3451	3454	the	the	DT
509	3455	3464	incidence	incidence	NN
510	3465	3467	of	of	IN
511	3476	3481	fatal	fatal	JJ
512	3482	3484	or	or	CC
513	3485	3494	non-fatal	non-fatal	JJ
514	3495	3501	stroke	stroke	NN
515	3502	3504	by	by	IN
516	3505	3508	0.8	0.8	CD
519	3511	3514	0.8	0.8	CD
521	3516	3519	vs.	vs.	NN
522	3520	3523	1.6	1.6	CD
525	3526	3528	RR	rr	NNP
526	3529	3533	0.50	0.50	CD
528	3543	3545	95	95	CD
530	3547	3549	CI	cus	NNP
531	3550	3554	0.26	0.26	CD
533	3555	3559	0.99	0.99	CD
537	3565	3570	0.045	0.045	CD
540	3573	3585	Atorvastatin	atorvastatin	NNP
541	3586	3590	also	also	RB
542	3599	3612	significantly	significantly	RB
543	3613	3620	reduced	reduce	VBN
544	3621	3626	total	total	JJ
545	3627	3630	and	and	CC
546	3631	3634	LDL	ldl	NNP
547	3635	3646	cholesterol	cholesterol	NN
548	3647	3650	and	and	CC
549	3659	3671	triglyceride	triglyceride	NN
550	3672	3678	levels	level	NNS
551	3679	3682	but	but	CC
552	3683	3686	did	do	VBD
553	3687	3690	not	not	RB
554	3691	3704	significantly	significantly	RB
555	3705	3711	change	change	VB
556	3712	3716	high	high	JJ
557	3725	3732	density	density	NN
558	3733	3744	lipoprotein	lipoprotein	NN
560	3746	3749	HDL	hdl	NNP
562	3751	3762	cholesterol	cholesterol	NN
563	3763	3765	by	by	IN
564	3766	3768	16	16	CD
565	3769	3774	weeks	week	NNS
567	3776	3778	By	by	IN
568	3779	3781	16	16	CD
569	3790	3795	weeks	week	NNS
571	3797	3800	the	the	DT
572	3801	3809	adjusted	adjusted	JJ
573	3810	3814	mean	mean	NN
574	3815	3818	LDL	ldl	NNP
575	3819	3830	cholesterol	cholesterol	NN
576	3831	3840	decreased	decrease	VBD
577	3841	3843	to	to	TO
578	3844	3846	72	72	CD
579	3855	3857	mg	mg	NN
581	3858	3860	dL	dl	NN
582	3861	3863	in	in	IN
583	3864	3884	atorvastatin-treated	atorvastatin-treat	JJ
584	3885	3893	patients	patient	NNS
585	3894	3897	but	but	CC
586	3898	3907	increased	increase	VBN
587	3908	3910	to	to	TO
588	3911	3914	135	135	CD
589	3923	3925	mg	mg	NN
591	3926	3928	dL	dl	NN
592	3929	3934	among	among	IN
593	3935	3950	placebo-treated	placebo-treat	JJ
594	3951	3959	patients	patient	NNS
596	3961	3963	No	no	DT
597	3964	3971	serious	serious	JJ
598	3972	3979	adverse	adverse	JJ
599	3988	3994	events	event	NNS
600	3995	4003	occurred	occur	VBD
601	4004	4006	as	as	IN
602	4007	4010	the	the	DT
603	4011	4017	result	result	NN
604	4018	4020	of	of	IN
605	4021	4030	treatment	treatment	NN
606	4031	4035	with	with	IN
607	4044	4056	atorvastatin	atorvastatin	NN
609	4058	4066	although	although	IN
610	4067	4077	reversible	reversible	JJ
611	4078	4083	liver	liver	NN
612	4084	4096	transaminase	transaminase	NN
613	4105	4114	elevation	elevation	NN
614	4115	4119	more	more	JJR
615	4120	4124	than	than	IN
616	4125	4130	three	three	CD
617	4131	4136	times	time	NNS
618	4137	4140	the	the	DT
619	4141	4146	upper	upper	JJ
620	4147	4152	limit	limit	NN
621	4153	4155	of	of	IN
622	4156	4162	normal	normal	RB
623	4171	4179	occurred	occur	VBD
624	4180	4182	in	in	IN
625	4183	4186	2.5	2.5	CD
627	4188	4190	of	of	IN
628	4191	4211	atorvastatin-treated	atorvastatin-treat	JJ
629	4212	4218	versus	versus	CC
630	4219	4222	0.6	0.6	CD
632	4224	4226	of	of	IN
633	4235	4250	placebo-treated	placebo-treat	JJ
634	4251	4259	patients	patient	NNS
638	4265	4270	0.001	0.001	CD
641	4295	4298	The	the	DT
642	4299	4309	MIRACuLous	miraculous	NNP
643	4318	4321	The	the	DT
644	4322	4330	efficacy	efficacy	NN
645	4331	4334	and	and	CC
646	4335	4341	safety	safety	NN
647	4342	4350	findings	finding	NNS
648	4351	4355	from	from	IN
649	4356	4362	MIRACL	miracl	NNP
650	4363	4367	were	be	VBD
651	4368	4374	unique	unique	JJ
652	4383	4386	for	for	IN
653	4387	4388	a	a	DT
654	4389	4395	number	number	NN
655	4396	4398	of	of	IN
656	4399	4406	reasons	reason	NNS
658	4408	4416	Although	although	IN
659	4417	4431	lipid-lowering	lipid-lower	JJ
660	4432	4439	therapy	therapy	NN
661	4448	4451	was	be	VBD
662	4452	4462	associated	associate	VBN
663	4463	4467	with	with	IN
664	4468	4469	a	a	DT
665	4470	4483	significantly	significantly	RB
666	4484	4489	lower	lower	JJR
667	4490	4499	mortality	mortality	NN
668	4500	4504	when	when	WRB
669	4513	4522	initiated	initiate	VBN
670	4523	4528	early	early	RB
671	4529	4534	after	after	IN
672	4535	4537	an	an	DT
673	4538	4543	acute	acute	JJ
674	4544	4552	coronary	coronary	JJ
675	4553	4561	syndrome	syndrome	NN
676	4562	4564	in	in	IN
677	4565	4568	two	two	CD
678	4577	4582	large	large	JJ
679	4583	4596	observational	observational	NN
680	4597	4604	studies	study	NNS
682	4607	4608	6	6	CD
683	4609	4610	7	7	CD
686	4615	4621	MIRACL	miracl	NNP
687	4622	4625	was	be	VBD
688	4626	4629	the	the	DT
689	4630	4635	first	first	JJ
690	4644	4654	randomized	randomize	JJ
691	4655	4660	trial	trial	NN
692	4661	4663	to	to	TO
693	4664	4671	suggest	suggest	VB
694	4672	4676	that	that	IN
695	4677	4684	statins	statin	NNS
696	4685	4691	confer	confer	VBP
697	4692	4700	clinical	clinical	JJ
698	4709	4717	benefits	benefit	NNS
699	4718	4720	in	in	IN
700	4721	4725	this	this	DT
701	4726	4733	setting	set	VBG
703	4735	4737	It	it	PRP
704	4738	4741	was	be	VBD
705	4742	4746	also	also	RB
706	4747	4750	the	the	DT
707	4751	4756	first	first	JJ
708	4757	4762	trial	trial	NN
709	4763	4765	to	to	TO
710	4774	4782	identify	identify	VB
711	4783	4784	a	a	DT
712	4785	4795	short-term	short-term	JJ
714	4797	4799	ie	ie	NN
716	4801	4807	within	within	IN
717	4808	4810	16	16	CD
718	4811	4816	weeks	week	NNS
720	4818	4826	clinical	clinical	JJ
721	4835	4842	benefit	benefit	NN
722	4843	4847	from	from	IN
723	4848	4854	statin	statin	NN
724	4855	4862	therapy	therapy	NN
726	4864	4866	in	in	IN
727	4867	4875	previous	previous	JJ
728	4876	4885	secondary	secondary	JJ
729	4894	4904	prevention	prevention	NN
730	4905	4911	trials	trial	NNS
732	4913	4916	the	the	DT
733	4917	4924	benefit	benefit	NN
734	4925	4927	of	of	IN
735	4928	4934	statin	statin	NN
736	4935	4942	therapy	therapy	NN
737	4943	4946	was	be	VBD
738	4947	4950	not	not	RB
739	4959	4966	evident	evident	JJ
740	4967	4970	for	for	IN
741	4971	4974	one	one	CD
742	4975	4977	to	to	TO
743	4978	4981	two	two	CD
744	4982	4987	years	year	NNS
746	4989	4992	And	and	CC
748	4994	4999	while	while	IN
749	5000	5008	clinical	clinical	JJ
750	5009	5014	trial	trial	NN
751	5023	5029	safety	safety	NN
752	5030	5039	endpoints	endpoint	NNS
753	5040	5043	may	may	MD
754	5044	5046	be	be	VB
755	5047	5057	considered	consider	VBN
756	5058	5062	less	less	RBR
757	5063	5072	glamorous	glamorous	JJ
759	5074	5080	MIRACL	miracl	NNP
761	5091	5095	most	most	RBS
762	5096	5105	important	important	JJ
763	5106	5118	contribution	contribution	NN
764	5119	5122	may	may	MD
765	5123	5127	have	have	VB
766	5128	5132	been	be	VBN
767	5133	5137	that	that	IN
768	5138	5147	high-dose	high-dose	JJ
769	5156	5162	statin	statin	NN
770	5163	5170	therapy	therapy	NN
771	5171	5174	was	be	VBD
772	5175	5178	not	not	RB
773	5179	5189	associated	associate	VBN
774	5190	5194	with	with	IN
775	5195	5202	serious	serious	JJ
776	5203	5207	harm	harm	NN
778	5217	5224	despite	despite	IN
779	5225	5228	its	its	PRP$
780	5229	5232	use	use	NN
781	5233	5235	in	in	IN
782	5236	5239	the	the	DT
783	5240	5248	unstable	unstable	JJ
784	5249	5256	setting	set	NN
786	5258	5265	Earlier	earlier	RBR
787	5266	5275	secondary	secondary	JJ
788	5284	5294	prevention	prevention	NN
789	5295	5301	statin	statin	NN
790	5302	5308	trials	trial	NNS
791	5309	5312	had	have	VBD
792	5313	5321	excluded	exclude	VBN
793	5322	5330	patients	patient	NNS
794	5331	5335	with	with	IN
795	5344	5352	unstable	unstable	JJ
796	5353	5361	coronary	coronary	JJ
797	5362	5371	syndromes	syndrome	NNS
798	5372	5379	largely	largely	RB
799	5380	5383	out	out	IN
800	5384	5386	of	of	IN
801	5387	5398	theoretical	theoretical	JJ
802	5407	5414	concern	concern	NN
803	5415	5419	that	that	IN
804	5420	5435	statin-mediated	statin-mediate	JJ
805	5436	5446	reductions	reduction	NNS
806	5447	5449	in	in	IN
807	5450	5458	vascular	vascular	NN
808	5459	5465	smooth	smooth	JJ
809	5474	5480	muscle	muscle	NN
810	5481	5485	cell	cell	NN
811	5486	5499	proliferation	proliferation	NN
812	5500	5505	might	may	MD
813	5506	5517	destabilize	destabilize	VB
814	5518	5525	healing	heal	VBG
815	5526	5532	plaque	plaque	NN
817	5542	5546	That	that	DT
818	5547	5549	no	no	DT
819	5550	5554	harm	harm	NN
820	5555	5563	resulted	result	VBD
821	5564	5568	from	from	IN
822	5569	5573	this	this	DT
823	5574	5584	aggressive	aggressive	JJ
824	5585	5594	treatment	treatment	NN
825	5603	5611	strategy	strategy	NN
826	5612	5618	should	should	MD
827	5619	5624	allay	allay	VB
828	5625	5636	theoretical	theoretical	JJ
829	5637	5642	fears	fear	NNS
830	5643	5646	and	and	CC
831	5647	5649	by	by	IN
832	5650	5655	doing	do	VBG
833	5656	5658	so	so	RB
834	5667	5673	remove	remove	VB
835	5674	5675	a	a	DT
836	5676	5681	major	major	JJ
837	5682	5690	obstacle	obstacle	NN
838	5691	5693	to	to	TO
839	5694	5697	the	the	DT
840	5698	5707	inpatient	inpatient	NN
841	5708	5718	initiation	initiation	NN
842	5719	5721	of	of	IN
843	5730	5742	lipid-lowing	lipid-low	JJ
844	5743	5750	therapy	therapy	NN
845	5751	5756	after	after	IN
846	5757	5765	coronary	coronary	JJ
847	5766	5772	events	event	NNS
849	5796	5799	The	the	DT
850	5800	5803	not	not	RB
851	5804	5806	so	so	RB
852	5807	5817	MIRACuLous	miraculous	NNP
853	5826	5833	Despite	despite	IN
854	5834	5839	these	these	DT
855	5840	5846	unique	unique	JJ
856	5847	5850	and	and	CC
857	5851	5860	important	important	JJ
858	5861	5869	findings	finding	NNS
860	5871	5876	there	there	EX
861	5877	5881	were	be	VBD
862	5890	5891	a	a	DT
863	5892	5898	number	number	NN
864	5899	5901	of	of	IN
865	5902	5910	inherent	inherent	JJ
866	5911	5916	study	study	NN
867	5917	5928	limitations	limitation	NNS
868	5929	5934	worth	worth	JJ
869	5935	5941	noting	note	VBG
871	5943	5948	First	first	LS
872	5957	5960	and	and	CC
873	5961	5969	foremost	foremost	RB
875	5971	5974	the	the	DT
876	5975	5986	possibility	possibility	NN
877	5987	5989	of	of	IN
878	5990	5991	a	a	DT
879	5992	5996	null	null	NN
880	5997	6006	treatment	treatment	NN
881	6007	6013	effect	effect	NN
882	6022	6025	can	can	MD
883	6025	6028	not	not	RB
884	6029	6031	be	be	VB
885	6032	6039	ignored	ignore	VBN
886	6040	6045	given	give	VBN
887	6046	6049	the	the	DT
888	6050	6054	wide	wide	JJ
889	6055	6065	confidence	confidence	NN
890	6066	6075	intervals	interval	NNS
892	6077	6080	and	and	CC
893	6089	6094	hence	hence	RB
894	6095	6105	marginally	marginally	RB
895	6106	6117	significant	significant	JJ
897	6120	6125	value	value	NN
898	6126	6128	of	of	IN
899	6129	6134	0.048	0.048	CD
901	6136	6139	for	for	IN
902	6140	6143	the	the	DT
903	6152	6158	effect	effect	NN
904	6159	6161	of	of	IN
905	6162	6174	atorvastatin	atorvastatin	NN
906	6175	6177	on	on	IN
907	6178	6181	the	the	DT
908	6182	6189	primary	primary	JJ
909	6190	6198	efficacy	efficacy	NN
910	6199	6207	endpoint	endpoint	NN
912	6217	6228	Furthermore	furthermore	RB
914	6230	6235	while	while	IN
915	6236	6239	the	the	DT
916	6240	6246	number	number	NN
917	6247	6249	of	of	IN
918	6250	6258	patients	patient	NNS
919	6259	6263	lost	lose	VBD
920	6264	6266	to	to	TO
921	6267	6273	follow	follow	VB
922	6274	6276	up	up	RP
923	6285	6288	was	be	VBD
924	6289	6294	small	small	JJ
926	6296	6298	if	if	IN
927	6299	6306	adverse	adverse	JJ
928	6307	6313	events	event	NNS
929	6314	6317	had	have	VBD
930	6318	6326	occurred	occur	VBN
931	6327	6329	in	in	IN
932	6330	6335	those	those	DT
933	6336	6343	treated	treat	VBN
934	6352	6356	with	with	IN
935	6357	6369	atorvastatin	atorvastatin	NN
939	6375	6376	3	3	CD
941	6378	6381	but	but	CC
942	6382	6385	not	not	RB
943	6386	6393	placebo	placebo	NN
947	6399	6400	8	8	CD
950	6403	6406	the	the	DT
951	6415	6422	overall	overall	JJ
952	6423	6428	trial	trial	NN
953	6429	6436	results	result	NNS
954	6437	6440	may	may	MD
955	6441	6445	have	have	VB
956	6446	6450	been	be	VBN
957	6451	6458	neutral	neutral	JJ
958	6459	6465	rather	rather	RB
959	6466	6470	than	than	IN
960	6479	6487	positive	positive	NN
962	6497	6500	The	the	DT
963	6501	6506	types	type	NNS
964	6507	6509	of	of	IN
965	6510	6516	events	event	NNS
966	6517	6526	prevented	prevent	VBN
967	6527	6529	in	in	IN
968	6530	6536	MIRACL	miracl	NNP
969	6537	6540	are	be	VBP
970	6541	6545	also	also	RB
971	6546	6551	worth	worth	JJ
972	6560	6566	noting	note	VBG
974	6568	6573	While	while	IN
975	6574	6591	rehospitalization	rehospitalization	NN
976	6592	6595	for	for	IN
977	6596	6605	recurrent	recurrent	JJ
978	6606	6616	myocardial	myocardial	NN
979	6625	6633	ischemia	ischemium	NN
980	6634	6636	is	be	VBZ
981	6637	6639	an	an	DT
982	6640	6649	important	important	JJ
983	6650	6661	determinant	determinant	NN
984	6662	6664	of	of	IN
985	6665	6672	quality	quality	NN
986	6673	6675	of	of	IN
987	6676	6680	life	life	NN
988	6681	6684	and	and	CC
989	6693	6699	health	health	NN
990	6700	6704	care	care	NN
991	6705	6710	costs	cost	NNS
993	6712	6717	other	other	JJ
994	6718	6727	important	important	JJ
995	6728	6737	endpoints	endpoint	NNS
996	6738	6742	were	be	VBD
997	6743	6746	not	not	RB
998	6755	6768	significantly	significantly	RB
999	6769	6777	affected	affect	VBN
1001	6779	6781	eg	eg	NN
1003	6783	6788	death	death	NN
1005	6790	6800	myocardial	myocardial	NN
1006	6801	6811	infarction	infarction	NN
1008	6821	6833	resuscitated	resuscitate	JJ
1009	6834	6840	sudden	sudden	JJ
1010	6841	6848	cardiac	cardiac	JJ
1011	6849	6854	death	death	NN
1013	6856	6865	worsening	worsen	VBG
1014	6866	6871	heart	heart	NN
1015	6872	6879	failure	failure	NN
1017	6889	6893	need	need	NN
1018	6894	6897	for	for	IN
1019	6898	6906	coronary	coronary	JJ
1020	6907	6924	revascularization	revascularization	NN
1022	6926	6929	etc	etc	FW
1025	6932	6935	The	the	DT
1026	6936	6944	question	question	NN
1027	6945	6947	of	of	IN
1028	6956	6963	whether	whether	IN
1029	6964	6971	statins	statin	NNS
1030	6972	6975	can	can	MD
1031	6976	6983	prevent	prevent	VB
1032	6984	6989	these	these	DT
1033	6990	6993	and	and	CC
1034	6994	6999	other	other	JJ
1035	7000	7007	adverse	adverse	JJ
1036	7008	7014	events	event	NNS
1037	7023	7027	when	when	WRB
1038	7028	7037	initiated	initiate	VBN
1039	7038	7042	soon	soon	RB
1040	7043	7048	after	after	IN
1041	7049	7051	an	an	DT
1042	7052	7057	acute	acute	JJ
1043	7058	7066	coronary	coronary	JJ
1044	7067	7075	syndrome	syndrome	NN
1045	7076	7080	will	will	MD
1046	7089	7096	require	require	VB
1047	7097	7104	further	further	JJ
1048	7105	7110	study	study	NN
1050	7120	7123	The	the	DT
1051	7124	7129	short	short	JJ
1052	7130	7138	duration	duration	NN
1053	7139	7141	of	of	IN
1054	7142	7151	follow-up	follow-up	JJ
1055	7152	7154	is	be	VBZ
1056	7155	7159	also	also	RB
1057	7160	7172	particularly	particularly	RB
1058	7181	7190	troubling	trouble	JJ
1060	7192	7197	While	while	IN
1061	7198	7200	it	it	PRP
1062	7201	7203	is	be	VBZ
1063	7204	7214	impressive	impressive	JJ
1064	7215	7219	that	that	IN
1065	7220	7221	a	a	DT
1066	7222	7230	clinical	clinical	JJ
1067	7231	7238	benefit	benefit	NN
1068	7247	7250	was	be	VBD
1069	7251	7259	realized	realize	VBN
1070	7260	7265	after	after	IN
1071	7266	7270	only	only	RB
1072	7271	7273	16	16	CD
1073	7274	7279	weeks	week	NNS
1074	7280	7282	of	of	IN
1075	7283	7289	statin	statin	NN
1076	7290	7297	therapy	therapy	NN
1078	7299	7302	the	the	DT
1079	7311	7320	increased	increased	JJ
1080	7321	7325	risk	risk	NN
1081	7326	7328	of	of	IN
1082	7329	7336	adverse	adverse	JJ
1083	7337	7345	clinical	clinical	JJ
1084	7346	7352	events	event	NNS
1085	7353	7361	persists	persist	VBZ
1086	7370	7380	throughout	throughout	IN
1087	7381	7384	the	the	DT
1088	7385	7389	year	year	NN
1089	7390	7399	following	follow	VBG
1090	7400	7402	an	an	DT
1091	7403	7408	acute	acute	JJ
1092	7409	7417	coronary	coronary	JJ
1093	7418	7426	syndrome	syndrome	NN
1095	7436	7443	Without	without	IN
1096	7444	7450	longer	longer	RBR
1097	7451	7459	clinical	clinical	JJ
1098	7460	7466	follow	follow	VB
1099	7467	7469	up	up	RB
1101	7471	7473	it	it	PRP
1102	7474	7476	is	be	VBZ
1103	7477	7480	not	not	RB
1104	7481	7489	possible	possible	JJ
1105	7490	7492	to	to	TO
1106	7501	7507	assess	assess	VB
1107	7508	7511	the	the	DT
1108	7512	7529	intermediate-term	intermediate-term	JJ
1109	7530	7536	effect	effect	NN
1111	7538	7540	if	if	IN
1112	7541	7544	any	any	DT
1114	7546	7548	of	of	IN
1115	7557	7569	atorvastatin	atorvastatin	NN
1116	7570	7572	on	on	IN
1117	7573	7577	hard	hard	JJ
1118	7578	7587	endpoints	endpoint	NNS
1119	7588	7592	such	such	JJ
1120	7593	7595	as	as	IN
1121	7596	7601	death	death	NN
1122	7602	7604	or	or	CC
1123	7605	7615	myocardial	myocardial	NN
1124	7624	7634	infarction	infarction	NN
1126	7636	7638	To	to	TO
1127	7639	7641	do	do	VB
1128	7642	7644	so	so	RB
1129	7645	7650	would	would	MD
1130	7651	7653	be	be	VB
1131	7654	7662	critical	critical	JJ
1132	7663	7665	in	in	IN
1133	7666	7671	light	light	NN
1134	7672	7674	of	of	IN
1135	7675	7678	the	the	DT
1136	7679	7683	lack	lack	NN
1137	7692	7694	of	of	IN
1138	7695	7701	effect	effect	NN
1139	7702	7704	on	on	IN
1140	7705	7710	these	these	DT
1141	7711	7720	important	important	JJ
1142	7721	7730	endpoints	endpoint	NNS
1143	7731	7733	at	at	IN
1144	7734	7736	16	16	CD
1145	7737	7742	weeks	week	NNS
1147	7752	7765	Unfortunately	unfortunately	RB
1149	7767	7769	no	no	DT
1150	7770	7774	late	late	JJ
1151	7775	7783	clinical	clinical	JJ
1152	7784	7790	follow	follow	VB
1153	7791	7793	up	up	RB
1154	7794	7796	is	be	VBZ
1155	7797	7804	planned	plan	VBN
1157	7814	7819	There	there	EX
1158	7820	7824	were	be	VBD
1159	7825	7829	also	also	RB
1160	7830	7831	a	a	DT
1161	7832	7838	number	number	NN
1162	7839	7841	of	of	IN
1163	7842	7853	limitations	limitation	NNS
1164	7854	7858	that	that	WDT
1165	7859	7862	may	may	MD
1166	7863	7867	have	have	VB
1167	7876	7884	hampered	hamper	VBN
1168	7885	7888	the	the	DT
1169	7889	7894	study	study	NN
1171	7897	7913	generalizability	generalizability	NN
1173	7915	7920	First	first	LS
1175	7922	7930	patients	patient	NNS
1176	7931	7934	who	who	WP
1177	7943	7952	underwent	undergo	VBD
1178	7953	7959	recent	recent	JJ
1179	7960	7977	revascularization	revascularization	NN
1180	7978	7980	or	or	CC
1181	7981	7983	in	in	IN
1182	7984	7988	whom	whom	WP
1183	7989	7991	it	it	PRP
1184	7992	7995	was	be	VBD
1185	8004	8011	planned	plan	VBN
1186	8012	8016	were	be	VBD
1187	8017	8025	excluded	exclude	VBN
1189	8027	8039	Specifically	specifically	RB
1191	8041	8049	patients	patient	NNS
1192	8050	8053	who	who	WP
1193	8054	8063	underwent	undergo	VBD
1194	8072	8084	percutaneous	percutaneous	JJ
1195	8085	8097	transluminal	transluminal	NN
1196	8098	8106	coronary	coronary	JJ
1197	8107	8118	angioplasty	angioplasty	NN
1199	8120	8124	PTCA	ptca	NNP
1201	8126	8128	or	or	CC
1202	8137	8145	coronary	coronary	JJ
1203	8146	8152	artery	artery	NN
1204	8153	8159	bypass	bypass	NN
1205	8160	8165	graft	graft	NN
1207	8167	8171	CABG	cabg	NNP
1209	8173	8180	surgery	surgery	NN
1210	8181	8187	within	within	IN
1211	8188	8191	the	the	DT
1212	8200	8208	previous	previous	JJ
1213	8209	8214	three	three	CD
1214	8215	8217	or	or	CC
1215	8218	8221	six	six	CD
1216	8222	8228	months	month	NNS
1217	8229	8241	respectively	respectively	RB
1218	8242	8246	were	be	VBD
1219	8247	8250	not	not	RB
1220	8251	8259	eligible	eligible	JJ
1221	8268	8271	for	for	IN
1222	8272	8281	inclusion	inclusion	NN
1224	8283	8286	The	the	DT
1225	8287	8300	investigators	investigator	NNS
1226	8301	8309	reasoned	reason	VBD
1227	8310	8314	that	that	IN
1228	8315	8324	recurrent	recurrent	JJ
1229	8333	8341	ischemic	ischemic	JJ
1230	8342	8348	events	event	NNS
1231	8349	8351	in	in	IN
1232	8352	8356	this	this	DT
1233	8357	8367	population	population	NN
1234	8368	8372	were	be	VBD
1235	8373	8379	likely	likely	JJ
1236	8380	8382	to	to	TO
1237	8383	8389	result	result	VB
1238	8398	8402	from	from	IN
1239	8403	8413	restenosis	restenosis	NNS
1240	8414	8416	or	or	CC
1241	8417	8423	bypass	bypass	VB
1242	8424	8429	graft	graft	NN
1243	8430	8437	closure	closure	NN
1244	8438	8441	and	and	CC
1245	8442	8446	that	that	IN
1246	8447	8454	statins	statin	NNS
1247	8463	8468	would	would	MD
1248	8469	8471	be	be	VB
1249	8472	8476	less	less	RBR
1250	8477	8483	likely	likely	JJ
1251	8484	8486	to	to	TO
1252	8487	8493	affect	affect	VB
1253	8494	8499	these	these	DT
1254	8500	8509	processes	process	VBZ
1256	8512	8513	8	8	CD
1259	8526	8538	Nevertheless	nevertheless	RB
1261	8540	8541	a	a	DT
1262	8542	8548	number	number	NN
1263	8549	8551	of	of	IN
1264	8552	8558	trials	trial	NNS
1265	8559	8563	have	have	VBP
1266	8564	8575	established	establish	VBN
1267	8576	8579	the	the	DT
1268	8588	8596	benefits	benefit	NNS
1269	8597	8599	of	of	IN
1270	8600	8606	statin	statin	NN
1271	8607	8614	therapy	therapy	NN
1272	8624	8629	early	early	RB
1273	8630	8635	after	after	IN
1274	8636	8644	coronary	coronary	JJ
1275	8653	8670	revascularization	revascularization	NN
1277	8673	8674	9	9	CD
1278	8675	8677	10	10	CD
1279	8678	8680	11	11	CD
1282	8685	8696	Furthermore	furthermore	RB
1284	8698	8699	a	a	DT
1285	8700	8706	number	number	NN
1286	8707	8709	of	of	IN
1287	8718	8724	recent	recent	JJ
1288	8725	8731	trials	trial	NNS
1289	8732	8736	have	have	VBP
1290	8737	8746	suggested	suggest	VBN
1291	8747	8751	that	that	IN
1292	8752	8758	higher	higher	JJR
1293	8759	8763	risk	risk	NN
1294	8764	8772	patients	patient	NNS
1295	8773	8777	with	with	IN
1296	8786	8790	non-	non-	NN
1297	8790	8792	ST	st	NNP
1298	8793	8802	elevation	elevation	NN
1299	8803	8808	acute	acute	JJ
1300	8809	8817	coronary	coronary	JJ
1301	8818	8827	syndromes	syndrome	NNS
1302	8828	8832	fair	fair	JJ
1303	8833	8839	better	better	JJR
1304	8840	8844	when	when	WRB
1305	8853	8855	an	an	DT
1306	8856	8861	early	early	JJ
1307	8862	8870	invasive	invasive	JJ
1308	8871	8879	strategy	strategy	NN
1309	8880	8882	is	be	VBZ
1310	8883	8890	applied	apply	VBN
1312	8893	8895	12	12	CD
1313	8896	8898	13	13	CD
1314	8899	8901	14	14	CD
1316	8904	8907	and	and	CC
1317	8908	8910	it	it	PRP
1318	8919	8921	is	be	VBZ
1319	8922	8925	not	not	RB
1320	8926	8934	uncommon	uncommon	JJ
1321	8935	8938	for	for	IN
1322	8939	8947	patients	patient	NNS
1323	8948	8950	to	to	TO
1324	8951	8953	be	be	VB
1325	8954	8961	treated	treat	VBN
1326	8962	8964	in	in	IN
1327	8965	8969	this	this	DT
1328	8970	8977	fashion	fashion	NN
1330	8987	8993	Second	second	JJ
1332	8995	9003	patients	patient	NNS
1333	9004	9008	with	with	IN
1334	9009	9011	Q-	q-	NNP
1335	9011	9015	wave	wave	NN
1336	9016	9026	myocardial	myocardial	NN
1337	9027	9037	infarction	infarction	NN
1338	9038	9042	were	be	VBD
1339	9043	9046	not	not	RB
1340	9055	9063	eligible	eligible	JJ
1341	9064	9067	for	for	IN
1342	9068	9078	enrollment	enrollment	NN
1343	9079	9086	because	because	IN
1344	9087	9089	it	it	PRP
1345	9090	9093	was	be	VBD
1346	9094	9098	felt	feel	VBN
1347	9099	9103	that	that	IN
1348	9104	9111	statins	statin	NNS
1349	9120	9125	would	would	MD
1350	9126	9129	not	not	RB
1351	9130	9139	influence	influence	VB
1352	9140	9143	the	the	DT
1353	9144	9155	development	development	NN
1354	9156	9158	of	of	IN
1355	9159	9168	important	important	JJ
1356	9169	9179	prognostic	prognostic	JJ
1357	9188	9200	determinants	determinant	NNS
1358	9201	9205	such	such	JJ
1359	9206	9208	as	as	IN
1360	9209	9213	left	leave	VBN
1361	9214	9225	ventricular	ventricular	NN
1362	9226	9234	systolic	systolic	JJ
1363	9235	9246	dysfunction	dysfunction	NN
1365	9256	9267	ventricular	ventricular	NN
1366	9268	9279	arrhythmias	arrhythmia	NNS
1367	9280	9282	or	or	CC
1368	9283	9293	mechanical	mechanical	JJ
1369	9294	9307	complications	complication	NNS
1371	9310	9311	5	5	CD
1374	9324	9336	Nevertheless	nevertheless	RB
1376	9338	9346	patients	patient	NNS
1377	9347	9350	who	who	WP
1378	9351	9358	develop	develop	VBP
1379	9359	9379	electrocardiographic	electrocardiographic	JJ
1380	9388	9390	Q-	q-	NNP
1381	9390	9395	waves	wave	NNS
1382	9396	9405	represent	represent	VBP
1383	9406	9407	a	a	DT
1384	9408	9419	substantial	substantial	JJ
1385	9420	9430	proportion	proportion	NN
1386	9431	9433	of	of	IN
1387	9434	9437	all	all	DT
1388	9438	9446	patients	patient	NNS
1389	9455	9459	with	with	IN
1390	9460	9470	myocardial	myocardial	NN
1391	9471	9481	infarction	infarction	NN
1393	9483	9488	While	while	IN
1394	9489	9494	their	their	PRP$
1395	9495	9505	short-term	short-term	JJ
1396	9506	9510	risk	risk	NN
1397	9519	9528	following	follow	VBG
1398	9529	9537	hospital	hospital	NN
1399	9538	9547	discharge	discharge	NN
1400	9548	9550	is	be	VBZ
1401	9551	9556	lower	lower	JJR
1402	9557	9565	relative	relative	JJ
1403	9566	9568	to	to	TO
1404	9569	9574	those	those	DT
1405	9583	9587	with	with	IN
1406	9588	9589	a	a	DT
1407	9590	9594	non-	non-	NN
1408	9594	9596	Q-	q-	NNP
1409	9596	9600	wave	wave	NN
1410	9601	9611	myocardial	myocardial	NN
1411	9612	9622	infarction	infarction	NN
1413	9624	9626	it	it	PRP
1414	9627	9629	is	be	VBZ
1415	9630	9635	still	still	RB
1416	9636	9640	much	much	RB
1417	9649	9656	greater	greater	JJR
1418	9657	9661	than	than	IN
1419	9662	9664	in	in	IN
1420	9665	9673	patients	patient	NNS
1421	9674	9678	with	with	IN
1422	9679	9685	stable	stable	JJ
1423	9686	9694	coronary	coronary	JJ
1424	9695	9702	disease	disease	NN
1426	9704	9707	and	and	CC
1427	9716	9719	the	the	DT
1428	9720	9724	need	need	NN
1429	9725	9728	for	for	IN
1430	9729	9738	secondary	secondary	JJ
1431	9739	9749	prevention	prevention	NN
1432	9750	9752	in	in	IN
1433	9753	9757	this	this	DT
1434	9758	9768	population	population	NN
1435	9769	9771	is	be	VBZ
1436	9780	9787	equally	equally	RB
1437	9788	9797	important	important	JJ
1439	9799	9804	Third	third	NNP
1441	9806	9813	despite	despite	IN
1442	9814	9817	the	the	DT
1443	9818	9822	high	high	JJ
1444	9823	9827	risk	risk	NN
1445	9828	9834	nature	nature	NN
1446	9835	9837	of	of	IN
1447	9846	9854	enrolled	enroll	VBD
1448	9855	9863	patients	patient	NNS
1450	9865	9867	ie	ie	NN
1452	9869	9886	electrocardiogram	electrocardiogram	NN
1454	9888	9891	ECG	ecg	NNP
1456	9893	9900	changes	change	NNS
1457	9909	9912	and	and	CC
1459	9913	9915	or	or	CC
1460	9916	9921	other	other	JJ
1461	9922	9931	objective	objective	NN
1462	9932	9940	evidence	evidence	NN
1463	9941	9943	of	of	IN
1464	9944	9952	ischemia	ischemium	NN
1467	9955	9958	the	the	DT
1468	9959	9963	rate	rate	NN
1469	9964	9966	of	of	IN
1470	9975	9983	platelet	platelet	NN
1471	9984	9996	glycoprotein	glycoprotein	NN
1472	9997	10000	IIb	iib	NNP
1474	10001	10005	IIIa	iium	NNP
1475	10006	10015	inhibitor	inhibitor	NN
1476	10016	10027	utilization	utilization	NN
1477	10028	10031	was	be	VBD
1478	10040	10045	quite	quite	RB
1479	10046	10049	low	low	JJ
1481	10051	10054	1.1	1.1	CD
1485	10058	10062	Such	such	JJ
1486	10063	10070	therapy	therapy	NN
1487	10071	10078	appears	appear	VBZ
1488	10079	10081	to	to	TO
1489	10082	10084	be	be	VB
1490	10085	10089	cost	cost	VBN
1491	10090	10099	effective	effective	JJ
1493	10110	10112	15	15	CD
1494	10113	10115	16	16	CD
1497	10120	10130	especially	especially	RB
1498	10131	10136	among	among	IN
1499	10137	10141	high	high	JJ
1500	10142	10146	risk	risk	NN
1501	10147	10155	patients	patient	NNS
1502	10156	10159	and	and	CC
1503	10160	10162	is	be	VBZ
1504	10171	10182	recommended	recommend	VBN
1505	10183	10188	under	under	IN
1506	10189	10196	current	current	JJ
1507	10197	10205	American	american	NNP
1508	10206	10213	College	college	NNP
1509	10214	10216	of	of	IN
1510	10225	10235	Cardiology	cardiology	NNP
1512	10236	10244	American	american	NNP
1513	10245	10250	Heart	heart	NNP
1514	10251	10262	Association	association	NNP
1515	10263	10273	guidelines	guideline	NNS
1517	10276	10278	17	17	CD
1520	10291	10297	Fourth	fourth	JJ
1522	10299	10301	it	it	PRP
1523	10302	10305	may	may	MD
1524	10306	10309	not	not	RB
1525	10310	10312	be	be	VB
1526	10313	10321	possible	possible	JJ
1527	10322	10324	to	to	TO
1528	10325	10334	ascertain	ascertain	VB
1529	10335	10342	whether	whether	IN
1530	10343	10348	these	these	DT
1531	10357	10365	findings	finding	NNS
1532	10366	10371	apply	apply	VBP
1533	10372	10374	to	to	TO
1534	10375	10378	all	all	DT
1535	10379	10387	patients	patient	NNS
1536	10388	10392	with	with	IN
1537	10393	10399	recent	recent	JJ
1538	10400	10405	acute	acute	JJ
1539	10406	10414	coronary	coronary	JJ
1540	10423	10432	syndromes	syndrome	NNS
1541	10433	10443	regardless	regardless	RB
1542	10444	10446	of	of	IN
1543	10447	10455	baseline	baseline	NN
1544	10456	10461	lipid	lipid	NN
1545	10462	10468	levels	level	NNS
1547	10470	10473	The	the	DT
1548	10474	10479	small	small	JJ
1549	10488	10498	difference	difference	NN
1550	10499	10501	in	in	IN
1551	10502	10508	number	number	NN
1552	10509	10511	of	of	IN
1553	10512	10519	primary	primary	JJ
1554	10520	10528	endpoint	endpoint	NN
1555	10529	10535	events	event	NNS
1556	10536	10543	between	between	IN
1557	10552	10564	atorvastatin	atorvastatin	NN
1558	10565	10568	and	and	CC
1559	10569	10576	placebo	placebo	NN
1560	10577	10583	groups	group	NNS
1561	10584	10588	make	make	VBP
1562	10589	10591	it	it	PRP
1563	10592	10601	difficult	difficult	JJ
1564	10602	10604	to	to	TO
1565	10613	10620	dissect	dissect	NN
1566	10621	10624	the	the	DT
1567	10625	10637	relationship	relationship	NN
1568	10638	10645	between	between	IN
1569	10646	10654	baseline	baseline	NN
1570	10655	10660	lipid	lipid	NN
1571	10661	10667	levels	level	NNS
1572	10668	10671	and	and	CC
1573	10680	10689	treatment	treatment	NN
1574	10690	10696	effect	effect	NN
1575	10697	10704	further	further	RB
1577	10706	10718	Consequently	consequently	RB
1579	10720	10722	it	it	PRP
1580	10723	10730	remains	remains	VBZ
1581	10739	10748	uncertain	uncertain	JJ
1582	10749	10756	whether	whether	IN
1583	10757	10760	one	one	PRP
1584	10761	10764	can	can	MD
1585	10765	10776	extrapolate	extrapolate	NN
1586	10777	10780	the	the	DT
1587	10781	10787	MIRACL	miracl	NNP
1588	10788	10793	trial	trial	NN
1589	10802	10809	results	result	NNS
1590	10810	10812	to	to	TO
1591	10813	10818	those	those	DT
1592	10819	10822	who	who	WP
1593	10823	10830	undergo	undergo	VBP
1594	10831	10839	coronary	coronary	JJ
1595	10840	10857	revascularization	revascularization	NN
1596	10866	10873	shortly	shortly	RB
1597	10874	10880	before	before	IN
1598	10881	10883	or	or	CC
1599	10884	10889	after	after	IN
1600	10890	10891	a	a	DT
1601	10892	10900	coronary	coronary	JJ
1602	10901	10906	event	event	NN
1604	10908	10911	who	who	WP
1605	10912	10919	present	present	JJ
1606	10920	10924	with	with	IN
1607	10933	10934	a	a	DT
1608	10935	10937	Q-	q-	NNP
1609	10937	10941	wave	wave	NN
1610	10942	10952	myocardial	myocardial	NN
1611	10953	10963	infarction	infarction	NN
1613	10965	10968	who	who	WP
1614	10969	10972	are	be	VBP
1615	10973	10980	treated	treat	VBN
1616	10981	10985	with	with	IN
1617	10994	11002	platelet	platelet	NN
1618	11003	11015	glycoprotein	glycoprotein	NN
1619	11016	11019	IIb	iib	NNP
1621	11020	11024	IIIa	iium	NNP
1622	11025	11035	inhibitors	inhibitor	NNS
1624	11037	11039	or	or	CC
1625	11040	11043	who	who	WP
1626	11044	11048	have	have	VBP
1627	11057	11067	relatively	relatively	RB
1628	11068	11071	low	low	JJ
1629	11072	11081	admission	admission	NN
1630	11082	11085	LDL	ldl	NNP
1631	11086	11097	cholesterol	cholesterol	NN
1632	11098	11104	levels	level	NNS
1634	11128	11132	Time	time	NNP
1635	11133	11135	to	to	TO
1636	11136	11142	change	change	VB
1637	11143	11150	current	current	JJ
1638	11151	11159	practice	practice	NN
1639	11168	11176	Although	although	IN
1640	11177	11183	MIRACL	miracl	NNP
1641	11184	11187	and	and	CC
1642	11188	11191	the	the	DT
1643	11192	11195	two	two	CD
1644	11196	11210	aforementioned	aforemention	JJ
1645	11211	11217	cohort	cohort	NN
1646	11226	11233	studies	study	NNS
1647	11234	11241	suggest	suggest	VBP
1648	11242	11246	that	that	IN
1649	11247	11261	lipid-lowering	lipid-lower	JJ
1650	11262	11268	agents	agent	NNS
1651	11269	11274	exert	exert	VB
1652	11275	11285	short-term	short-term	JJ
1653	11294	11302	clinical	clinical	JJ
1654	11303	11311	benefits	benefit	NNS
1655	11312	11316	when	when	WRB
1656	11317	11326	initiated	initiate	VBN
1657	11327	11331	soon	soon	RB
1658	11332	11337	after	after	IN
1659	11338	11340	an	an	DT
1660	11341	11346	acute	acute	JJ
1661	11355	11363	coronary	coronary	JJ
1662	11364	11372	syndrome	syndrome	NN
1664	11374	11378	this	this	DT
1665	11379	11386	remains	remains	VBZ
1666	11387	11389	an	an	DT
1667	11390	11394	open	open	JJ
1668	11395	11403	question	question	NN
1670	11405	11409	Even	even	RB
1671	11410	11412	if	if	IN
1672	11421	11426	these	these	DT
1673	11427	11435	findings	finding	NNS
1674	11436	11439	are	be	VBP
1675	11440	11443	not	not	RB
1676	11444	11453	confirmed	confirm	VBN
1677	11454	11459	after	after	IN
1678	11460	11467	further	further	JJ
1679	11468	11473	study	study	NN
1681	11475	11478	one	one	PRP
1682	11487	11492	could	could	MD
1683	11493	11498	still	still	RB
1684	11499	11503	make	make	VB
1685	11504	11505	a	a	DT
1686	11506	11516	compelling	compell	JJ
1687	11517	11525	argument	argument	NN
1688	11526	11530	that	that	IN
1689	11531	11545	lipid-lowering	lipid-lower	JJ
1690	11554	11561	therapy	therapy	NN
1692	11563	11570	barring	bar	VBG
1693	11571	11588	contraindications	contraindication	NNS
1695	11590	11596	should	should	MD
1696	11597	11599	be	be	VB
1697	11600	11609	initiated	initiate	VBN
1698	11618	11623	early	early	JJ
1699	11624	11627	and	and	CC
1700	11628	11639	universally	universally	RB
1701	11640	11642	in	in	IN
1702	11643	11651	patients	patient	NNS
1703	11652	11655	who	who	WP
1704	11656	11663	present	present	JJ
1705	11664	11668	with	with	IN
1706	11669	11671	an	an	DT
1707	11672	11677	acute	acute	JJ
1708	11686	11694	coronary	coronary	JJ
1709	11695	11703	syndrome	syndrome	NN
1711	11705	11710	First	first	CD
1713	11712	11715	the	the	DT
1714	11716	11725	long-term	long-term	JJ
1715	11726	11732	safety	safety	NN
1716	11733	11736	and	and	CC
1717	11745	11758	effectiveness	effectiveness	NN
1718	11759	11761	of	of	IN
1719	11762	11769	statins	statin	NNS
1720	11770	11773	for	for	IN
1721	11774	11777	the	the	DT
1722	11778	11787	secondary	secondary	JJ
1723	11788	11798	prevention	prevention	NN
1724	11799	11801	of	of	IN
1725	11811	11817	stable	stable	JJ
1726	11818	11826	coronary	coronary	JJ
1727	11827	11834	disease	disease	NN
1728	11835	11837	is	be	VBZ
1729	11846	11862	well-established	well-establish	JJ
1731	11865	11866	1	1	CD
1732	11867	11868	2	2	CD
1733	11869	11870	3	3	CD
1736	11875	11881	Second	second	JJ
1738	11883	11885	as	as	IN
1739	11886	11895	evidenced	evidence	VBN
1740	11896	11898	by	by	IN
1741	11907	11913	MIRACL	miracl	NNP
1743	11915	11920	these	these	DT
1744	11921	11927	agents	agent	NNS
1745	11928	11931	are	be	VBP
1746	11932	11936	safe	safe	JJ
1747	11937	11941	when	when	WRB
1748	11942	11951	initiated	initiate	VBN
1749	11952	11954	at	at	IN
1750	11955	11958	the	the	DT
1751	11959	11963	time	time	NN
1752	11964	11966	of	of	IN
1753	11975	11990	hospitalization	hospitalization	NN
1754	11991	11994	for	for	IN
1755	11995	11997	an	an	DT
1756	11998	12003	acute	acute	JJ
1757	12004	12012	coronary	coronary	JJ
1758	12013	12021	syndrome	syndrome	NN
1760	12023	12028	Third	third	NNP
1762	12030	12033	the	the	DT
1763	12042	12053	in-hospital	in-hospital	JJ
1764	12054	12064	initiation	initiation	NN
1765	12065	12067	of	of	IN
1766	12068	12082	lipid-lowering	lipid-lower	JJ
1767	12083	12090	therapy	therapy	NN
1768	12091	12098	appears	appear	VBZ
1769	12099	12101	to	to	TO
1770	12110	12117	promote	promote	VB
1771	12118	12125	greater	greater	JJR
1772	12126	12135	long-term	long-term	JJ
1773	12136	12147	utilization	utilization	NN
1774	12148	12150	of	of	IN
1775	12151	12156	these	these	DT
1776	12157	12163	agents	agent	NNS
1778	12166	12168	18	18	CD
1779	12177	12179	19	19	CD
1780	12180	12182	20	20	CD
1781	12183	12185	21	21	CD
1784	12190	12197	Finally	finally	RB
1786	12199	12207	although	although	IN
1787	12208	12213	lipid	lipid	NN
1788	12214	12220	levels	level	NNS
1789	12221	12224	may	may	MD
1790	12225	12227	be	be	VB
1791	12236	12246	unreliable	unreliable	JJ
1792	12247	12249	in	in	IN
1793	12250	12253	the	the	DT
1794	12254	12261	setting	set	NN
1795	12262	12264	of	of	IN
1796	12265	12267	an	an	DT
1797	12268	12273	acute	acute	JJ
1798	12274	12282	coronary	coronary	JJ
1799	12283	12291	syndrome	syndrome	NN
1801	12301	12310	excepting	except	VBG
1802	12311	12316	total	total	JJ
1804	12318	12321	HDL	hdl	NNP
1805	12322	12325	and	and	CC
1806	12326	12329	LDL	ldl	NNP
1808	12330	12333	HDL	hdl	NNP
1809	12334	12345	cholesterol	cholesterol	NN
1810	12346	12352	ratios	ratio	NNS
1812	12355	12357	22	22	CD
1815	12370	12373	the	the	DT
1816	12374	12386	overwhelming	overwhelm	JJ
1817	12387	12395	majority	majority	NN
1818	12396	12398	of	of	IN
1819	12399	12407	patients	patient	NNS
1820	12408	12412	with	with	IN
1821	12413	12421	coronary	coronary	JJ
1822	12430	12437	disease	disease	NN
1823	12438	12442	will	will	MD
1824	12443	12453	ultimately	ultimately	RB
1825	12454	12461	require	require	VB
1826	12462	12466	both	both	DT
1827	12467	12480	pharmacologic	pharmacologic	JJ
1828	12481	12484	and	and	CC
1829	12493	12510	non-pharmacologic	non-pharmacologic	JJ
1830	12511	12525	lipid-lowering	lipid-lower	JJ
1831	12526	12539	interventions	intervention	NNS
1832	12540	12542	to	to	TO
1833	12543	12549	attain	attain	VB
1834	12558	12569	recommended	recommend	VBD
1835	12570	12581	cholesterol	cholesterol	NN
1836	12582	12589	targets	target	NNS
1838	12592	12594	23	23	CD
1839	12595	12597	24	24	CD
1840	12598	12600	25	25	CD
1843	12605	12610	newer	newer	JJR
1844	12619	12629	guidelines	guideline	NNS
1845	12630	12633	are	be	VBP
1846	12634	12638	even	even	RB
1847	12639	12643	more	more	RBR
1848	12644	12653	stringent	stringent	JJ
1850	12656	12658	26	26	CD
1853	12663	12674	Furthermore	furthermore	RB
1855	12684	12688	data	datum	NNS
1856	12689	12693	from	from	IN
1857	12694	12697	the	the	DT
1858	12698	12706	recently	recently	RB
1859	12707	12716	presented	present	VBN
1860	12717	12722	Heart	heart	NNP
1861	12723	12733	Protection	protection	NNP
1862	12734	12739	Study	study	NNP
1863	12748	12755	suggest	suggest	VBP
1864	12756	12760	that	that	IN
1865	12761	12769	clinical	clinical	JJ
1866	12770	12778	benefits	benefit	NNS
1867	12779	12782	may	may	MD
1868	12783	12789	accrue	accrue	VB
1869	12790	12801	independent	independent	JJ
1870	12802	12804	of	of	IN
1871	12813	12821	baseline	baseline	NN
1872	12822	12833	cholesterol	cholesterol	NN
1873	12834	12839	level	level	NN
1875	12842	12843	4	4	CD
1878	12848	12852	Thus	thus	RB
1880	12854	12856	to	to	TO
1881	12857	12865	withhold	withhold	VB
1882	12874	12888	lipid-lowering	lipid-lower	JJ
1883	12889	12896	therapy	therapy	NN
1884	12897	12901	from	from	IN
1885	12902	12910	patients	patient	NNS
1886	12911	12914	who	who	WP
1887	12915	12922	present	present	JJ
1888	12923	12927	with	with	IN
1889	12928	12930	an	an	DT
1890	12939	12944	acute	acute	JJ
1891	12945	12953	coronary	coronary	JJ
1892	12954	12962	syndrome	syndrome	NN
1893	12963	12968	would	would	MD
1894	12969	12971	be	be	VB
1895	12972	12974	to	to	TO
1896	12975	12981	accept	accept	VB
1897	12982	12985	the	the	DT
1898	12986	12992	status	status	NN
1899	12993	12996	quo	quo	NN
1901	13006	13009	and	and	CC
1902	13010	13012	to	to	TO
1903	13013	13017	date	date	NN
1904	13018	13021	our	our	PRP$
1905	13022	13029	efforts	effort	NNS
1906	13030	13032	at	at	IN
1907	13033	13044	cholesterol	cholesterol	NN
1908	13045	13053	lowering	lower	VBG
1909	13054	13056	in	in	IN
1910	13057	13060	the	the	DT
1911	13069	13078	secondary	secondary	JJ
1912	13079	13089	prevention	prevention	NN
1913	13090	13097	setting	set	VBG
1914	13098	13102	have	have	VBP
1915	13103	13107	been	be	VBN
1916	13108	13114	dismal	dismal	JJ
1918	13117	13119	27	27	CD
1919	13120	13122	28	28	CD
1922	13157	13161	More	more	JJR
1923	13162	13170	MIRACLes	miracle	NNP
1924	13171	13176	ahead	ahead	RB
1926	13186	13189	The	the	DT
1927	13190	13203	ascertainment	ascertainment	NN
1928	13204	13207	and	and	CC
1929	13208	13222	quantification	quantification	NN
1930	13223	13225	of	of	IN
1931	13226	13229	any	any	DT
1932	13230	13241	incremental	incremental	JJ
1933	13250	13257	benefit	benefit	NN
1934	13258	13267	conferred	confer	VBD
1935	13268	13270	by	by	IN
1936	13271	13277	statin	statin	NN
1937	13278	13285	therapy	therapy	NN
1938	13286	13295	initiated	initiate	VBD
1939	13296	13301	early	early	RB
1940	13302	13307	after	after	IN
1941	13316	13318	an	an	DT
1942	13319	13324	acute	acute	JJ
1943	13325	13333	coronary	coronary	JJ
1944	13334	13342	syndrome	syndrome	NN
1945	13343	13347	will	will	MD
1946	13348	13355	require	require	VB
1947	13356	13368	confirmation	confirmation	NN
1949	13370	13375	There	there	EX
1950	13384	13386	is	be	VBZ
1951	13387	13396	currently	currently	RB
1952	13397	13401	only	only	RB
1953	13402	13405	one	one	CD
1954	13406	13413	ongoing	ongo	JJ
1955	13414	13424	randomized	randomize	JJ
1956	13425	13443	placebo-controlled	placebo-controll	JJ
1957	13452	13457	trial	trial	NN
1958	13458	13460	of	of	IN
1959	13461	13466	early	early	JJ
1960	13467	13473	versus	versus	CC
1961	13474	13481	delayed	delay	VBN
1962	13482	13488	statin	statin	NN
1963	13489	13496	therapy	therapy	NN
1964	13497	13499	in	in	IN
1965	13500	13504	this	this	DT
1966	13513	13520	setting	set	NN
1968	13522	13524	A-	a-	NNP
1969	13524	13525	2	2	CD
1973	13529	13538	Aggrastat	aggrastat	NNP
1974	13539	13541	to	to	TO
1975	13542	13547	Zocor	zocor	NNP
1977	13549	13554	Merck	merck	NNP
1980	13558	13560	29	29	CD
1983	13565	13568	The	the	DT
1984	13577	13579	A-	a-	NNP
1985	13579	13580	2	2	CD
1988	13583	13588	study	study	NN
1989	13589	13591	is	be	VBZ
1990	13592	13602	evaluating	evaluate	VBG
1991	13603	13606	the	the	DT
1992	13607	13615	efficacy	efficacy	NN
1993	13616	13618	of	of	IN
1994	13619	13624	early	early	JJ
1995	13625	13634	treatment	treatment	NN
1996	13643	13647	with	with	IN
1997	13648	13659	simvastatin	simvastatin	NN
1998	13660	13662	in	in	IN
1999	13663	13668	4,500	4,500	CD
2000	13669	13677	patients	patient	NNS
2001	13678	13687	following	follow	VBG
2002	13688	13690	an	an	DT
2003	13691	13698	episode	episode	NN
2004	13699	13701	of	of	IN
2005	13710	13718	unstable	unstable	JJ
2006	13719	13725	angina	angina	NN
2007	13726	13728	or	or	CC
2008	13729	13730	a	a	DT
2009	13731	13735	non-	non-	NN
2011	13737	13741	wave	wave	NN
2012	13742	13752	myocardial	myocardial	NN
2013	13753	13763	infarction	infarction	NN
2015	13765	13767	In	in	IN
2016	13776	13779	the	the	DT
2017	13780	13785	first	first	JJ
2018	13786	13790	four	four	CD
2019	13791	13797	months	month	NNS
2021	13799	13807	patients	patient	NNS
2022	13808	13812	will	will	MD
2023	13813	13815	be	be	VB
2024	13816	13826	randomized	randomize	JJ
2025	13827	13829	to	to	TO
2026	13838	13849	simvastatin	simvastatin	NN
2027	13850	13852	40	40	CD
2028	13853	13855	mg	mg	NN
2029	13856	13861	daily	daily	NN
2030	13862	13864	or	or	CC
2031	13865	13872	placebo	placebo	NN
2033	13874	13884	Thereafter	thereafter	RB
2035	13886	13891	those	those	DT
2036	13900	13908	patients	patient	NNS
2037	13909	13916	treated	treat	VBN
2038	13917	13921	with	with	IN
2039	13922	13933	simvastatin	simvastatin	NN
2040	13934	13936	in	in	IN
2041	13937	13940	the	the	DT
2042	13941	13946	first	first	JJ
2043	13947	13952	phase	phase	NN
2044	13953	13957	will	will	MD
2045	13966	13973	receive	receive	VB
2046	13974	13976	80	80	CD
2047	13977	13979	mg	mg	NN
2048	13980	13982	of	of	IN
2049	13983	13994	simvastatin	simvastatin	NN
2050	13995	14000	daily	daily	JJ
2051	14001	14004	and	and	CC
2052	14005	14010	those	those	DT
2053	14011	14018	treated	treat	VBN
2054	14019	14023	with	with	IN
2055	14032	14039	placebo	placebo	NN
2057	14041	14043	40	40	CD
2058	14044	14046	mg	mg	NN
2059	14047	14049	of	of	IN
2060	14050	14061	simvastatin	simvastatin	NN
2061	14062	14067	daily	daily	RB
2063	14069	14072	The	the	DT
2064	14073	14080	primary	primary	JJ
2065	14081	14090	composite	composite	JJ
2066	14099	14107	endpoint	endpoint	NN
2067	14108	14110	is	be	VBZ
2068	14111	14114	the	the	DT
2069	14115	14125	occurrence	occurrence	NN
2070	14126	14128	of	of	IN
2071	14129	14143	cardiovascular	cardiovascular	JJ
2072	14144	14149	death	death	NN
2074	14159	14168	non-fatal	non-fatal	JJ
2075	14169	14179	myocardial	myocardial	NN
2076	14180	14190	infarction	infarction	NN
2078	14192	14194	or	or	CC
2079	14195	14212	rehospitalization	rehospitalization	NN
2080	14213	14216	for	for	IN
2081	14225	14227	an	an	DT
2082	14228	14233	acute	acute	JJ
2083	14234	14242	coronary	coronary	JJ
2084	14243	14251	syndrome	syndrome	NN
2086	14253	14256	ACS	ac	NNP
2088	14258	14260	at	at	IN
2089	14261	14264	one	one	CD
2090	14265	14269	year	year	NN
2092	14271	14273	If	if	IN
2093	14274	14276	A-	a-	NNP
2094	14276	14277	2	2	CD
2097	14288	14300	demonstrates	demonstrate	VBZ
2098	14301	14312	significant	significant	JJ
2099	14313	14323	reductions	reduction	NNS
2100	14324	14326	in	in	IN
2101	14327	14330	the	the	DT
2102	14331	14340	incidence	incidence	NN
2103	14341	14343	of	of	IN
2104	14352	14359	adverse	adverse	JJ
2105	14360	14366	events	event	NNS
2106	14367	14373	during	during	IN
2107	14374	14377	the	the	DT
2108	14378	14383	first	first	JJ
2109	14384	14388	four	four	CD
2110	14389	14395	months	month	NNS
2112	14397	14399	it	it	PRP
2113	14400	14405	would	would	MD
2114	14414	14421	suggest	suggest	VB
2115	14422	14424	an	an	DT
2116	14425	14436	incremental	incremental	JJ
2117	14437	14445	clinical	clinical	JJ
2118	14446	14453	benefit	benefit	NN
2119	14454	14458	from	from	IN
2120	14459	14469	initiating	initiate	VBG
2121	14478	14483	these	these	DT
2122	14484	14490	agents	agent	NNS
2123	14491	14496	early	early	RB
2124	14497	14502	after	after	IN
2125	14503	14505	an	an	DT
2126	14506	14511	acute	acute	JJ
2127	14512	14520	coronary	coronary	JJ
2128	14521	14529	syndrome	syndrome	NN
2130	14531	14533	If	if	IN
2131	14542	14550	benefits	benefit	NNS
2132	14551	14557	accrue	accrue	VB
2134	14559	14562	but	but	CC
2135	14563	14565	do	do	VBP
2136	14566	14568	so	so	RB
2137	14569	14574	later	later	RB
2138	14575	14581	during	during	IN
2139	14582	14588	follow	follow	VB
2140	14589	14591	up	up	RB
2142	14593	14595	it	it	PRP
2143	14596	14601	would	would	MD
2144	14610	14612	be	be	VB
2145	14613	14622	difficult	difficult	JJ
2146	14623	14625	to	to	TO
2147	14626	14638	discriminate	discriminate	JJ
2148	14639	14646	between	between	IN
2149	14647	14650	the	the	DT
2150	14651	14658	effects	effect	NNS
2151	14659	14661	of	of	IN
2152	14662	14666	more	more	RBR
2153	14675	14685	aggressive	aggressive	JJ
2154	14686	14689	vs.	vs.	NN
2155	14690	14697	earlier	earlier	JJR
2156	14698	14703	lipid	lipid	NN
2157	14704	14712	lowering	lower	VBG
2158	14713	14720	therapy	therapy	NN
2160	14730	14733	The	the	DT
2161	14734	14745	Pravastatin	pravastatin	NNP
2162	14746	14748	or	or	CC
2163	14749	14761	Atorvastatin	atorvastatin	NNP
2164	14762	14772	Evaluation	evaluation	NNP
2165	14773	14776	and	and	CC
2166	14777	14786	Infection	infection	NNP
2167	14795	14802	Therapy	therapy	NNP
2169	14804	14809	PROVE	prove	NNP
2170	14810	14812	IT	it	PRP
2172	14814	14819	trial	trial	NN
2173	14820	14822	is	be	VBZ
2174	14823	14830	looking	look	VBG
2175	14831	14833	at	at	IN
2176	14834	14839	4,000	4,000	CD
2177	14840	14848	patients	patient	NNS
2178	14857	14863	within	within	IN
2179	14864	14866	10	10	CD
2180	14867	14871	days	day	NNS
2181	14872	14874	of	of	IN
2182	14875	14877	an	an	DT
2183	14878	14883	acute	acute	JJ
2184	14884	14892	coronary	coronary	JJ
2185	14893	14901	syndrome	syndrome	NN
2186	14902	14905	and	and	CC
2187	14914	14925	randomizing	randomize	VBG
2188	14926	14930	them	them	PRP
2189	14931	14933	to	to	TO
2190	14934	14940	either	either	CC
2191	14941	14952	pravastatin	pravastatin	NN
2192	14953	14955	40	40	CD
2193	14956	14958	mg	mg	NN
2194	14959	14961	or	or	CC
2195	14970	14982	atorvastatin	atorvastatin	NN
2196	14983	14985	80	80	CD
2197	14986	14988	mg	mg	NN
2198	14989	14994	daily	daily	JJ
2200	14997	14999	29	29	CD
2203	15004	15012	Patients	patient	NNS
2204	15013	15017	will	will	MD
2205	15018	15020	be	be	VB
2206	15021	15029	observed	observe	VBN
2207	15038	15042	over	over	IN
2208	15043	15045	at	at	IN
2209	15046	15051	least	least	JJS
2210	15052	15055	1.5	1.5	CD
2211	15056	15061	years	year	NNS
2212	15062	15065	for	for	IN
2213	15066	15069	the	the	DT
2214	15070	15080	occurrence	occurrence	NN
2215	15081	15083	of	of	IN
2216	15084	15094	myocardial	myocardial	NN
2217	15103	15113	infarction	infarction	NN
2218	15114	15116	or	or	CC
2219	15117	15122	other	other	JJ
2220	15123	15137	cardiovascular	cardiovascular	JJ
2221	15138	15144	events	event	NNS
2223	15146	15152	Unlike	unlike	IN
2225	15154	15160	MIRACL	miracl	NNP
2226	15169	15172	and	and	CC
2227	15173	15176	the	the	DT
2228	15177	15179	A-	a-	NNP
2229	15179	15180	2	2	CD
2232	15183	15189	trials	trial	NNS
2234	15191	15195	this	this	DT
2235	15196	15201	study	study	NN
2236	15202	15206	will	will	MD
2237	15207	15210	not	not	RB
2238	15211	15217	assess	assess	VB
2239	15218	15221	the	the	DT
2240	15230	15238	efficacy	efficacy	NN
2241	15239	15241	of	of	IN
2242	15242	15247	early	early	JJ
2243	15248	15254	statin	statin	NN
2244	15255	15262	therapy	therapy	NN
2245	15263	15268	after	after	IN
2246	15269	15271	an	an	DT
2247	15272	15277	acute	acute	JJ
2248	15278	15286	coronary	coronary	JJ
2249	15295	15303	syndrome	syndrome	NN
2251	15305	15311	rather	rather	RB
2253	15313	15315	it	it	PRP
2254	15316	15320	will	will	MD
2255	15321	15328	examine	examine	VB
2256	15329	15332	the	the	DT
2257	15333	15337	role	role	NN
2258	15338	15340	of	of	IN
2259	15350	15354	more	more	JJR
2260	15355	15358	vs.	vs.	NN
2261	15368	15372	less	less	RBR
2262	15373	15383	aggressive	aggressive	JJ
2263	15384	15398	lipid-lowering	lipid-lower	JJ
2264	15399	15401	in	in	IN
2265	15410	15414	this	this	DT
2266	15415	15422	setting	set	VBG
2268	15432	15434	In	in	IN
2269	15435	15439	2002	2002	CD
2271	15441	15445	many	many	JJ
2272	15446	15451	would	would	MD
2273	15452	15460	consider	consider	VB
2274	15461	15463	it	it	PRP
2275	15464	15473	unethical	unethical	JJ
2276	15474	15476	to	to	TO
2277	15477	15485	withhold	withhold	VB
2278	15494	15501	statins	statin	NNS
2279	15502	15506	from	from	IN
2280	15507	15515	patients	patient	NNS
2281	15516	15520	with	with	IN
2282	15521	15532	established	establish	VBN
2283	15533	15541	coronary	coronary	JJ
2284	15542	15549	disease	disease	NN
2286	15559	15563	This	this	DT
2287	15564	15569	makes	make	VBZ
2288	15570	15572	it	it	PRP
2289	15573	15581	unlikely	unlikely	JJ
2290	15582	15586	that	that	IN
2291	15587	15597	additional	additional	JJ
2292	15598	15616	placebo-controlled	placebo-controll	JJ
2293	15625	15631	trials	trial	NNS
2294	15632	15636	will	will	MD
2295	15637	15639	be	be	VB
2296	15640	15647	carried	carry	VBN
2297	15648	15651	out	out	IN
2298	15652	15654	in	in	IN
2299	15655	15659	this	this	DT
2300	15660	15664	area	area	NN
2302	15666	15672	Future	future	NNP
2303	15673	15682	secondary	secondary	JJ
2304	15691	15701	prevention	prevention	NN
2305	15702	15709	studies	study	NNS
2306	15710	15716	should	should	MD
2307	15717	15721	look	look	VB
2308	15722	15724	at	at	IN
2309	15725	15733	patients	patient	NNS
2310	15734	15738	with	with	IN
2311	15739	15745	stable	stable	JJ
2312	15755	15757	or	or	CC
2313	15758	15766	unstable	unstable	JJ
2314	15767	15774	disease	disease	NN
2315	15775	15778	and	and	CC
2316	15779	15783	will	will	MD
2317	15784	15788	need	need	VB
2318	15789	15791	to	to	TO
2319	15800	15807	address	address	VB
2320	15808	15811	the	the	DT
2321	15812	15823	comparative	comparative	JJ
2322	15824	15832	efficacy	efficacy	NN
2323	15833	15835	of	of	IN
2324	15836	15845	different	different	JJ
2325	15846	15853	statins	statin	NNS
2327	15855	15857	or	or	CC
2328	15866	15871	newer	newer	JJR
2329	15872	15878	agents	agent	NNS
2332	15881	15887	assess	assess	VBP
2333	15888	15891	the	the	DT
2334	15892	15903	incremental	incremental	JJ
2335	15904	15911	benefit	benefit	NN
2336	15912	15914	of	of	IN
2337	15923	15934	combination	combination	NN
2338	15935	15942	therapy	therapy	NN
2340	15945	15947	30	30	CD
2342	15950	15953	and	and	CC
2343	15954	15963	determine	determine	VB
2344	15964	15971	whether	whether	IN
2345	15972	15977	there	there	EX
2346	15978	15980	is	be	VBZ
2347	15981	15982	a	a	DT
2348	15991	15996	serum	serum	NN
2349	15997	16008	cholesterol	cholesterol	NN
2351	16010	16015	floor	floor	NN
2353	16017	16022	below	below	IN
2354	16023	16028	which	which	WDT
2355	16029	16039	reductions	reduction	NNS
2356	16040	16043	are	be	VBP
2357	16052	16060	unlikely	unlikely	JJ
2358	16061	16063	to	to	TO
2359	16064	16071	provide	provide	VB
2360	16072	16079	further	further	JJ
2361	16080	16088	clinical	clinical	JJ
2362	16089	16096	benefit	benefit	NN
2364	16120	16129	Competing	compete	VBG
2365	16130	16139	interests	interest	VBZ
2366	16148	16150	Dr	dr	NNP
2367	16151	16157	Aronow	aronow	NNP
2368	16158	16161	has	have	VBZ
2369	16162	16170	received	receive	VBN
2370	16171	16180	honoraria	honorarium	NN
2371	16181	16183	as	as	IN
2372	16184	16185	a	a	DT
2373	16186	16193	speaker	speaker	NN
2374	16194	16197	and	and	CC
2375	16206	16214	advisory	advisory	JJ
2376	16215	16220	board	board	NN
2377	16221	16227	member	member	NN
2378	16228	16231	for	for	IN
2379	16232	16238	Pfizer	pfizer	NNP
2380	16239	16242	and	and	CC
2381	16243	16245	as	as	IN
2382	16246	16247	a	a	DT
2383	16248	16255	speaker	speaker	NN
2384	16256	16259	for	for	IN
2385	16268	16273	Merck	merck	NNP
2387	16297	16310	Abbreviations	abbreviation	NNP
2388	16319	16322	HMG	hmg	NNP
2389	16323	16326	CoA	coa	NNP
2391	16329	16355	3-Hydroxy-3-methylgluatryl	3-hydroxy-3-methylgluatryl	NN
2392	16356	16364	coenzyme	coenzyme	NN
2395	16368	16374	MIRACL	miracl	NNP
2397	16385	16395	Myocardial	myocardial	NNP
2398	16396	16404	Ischemia	ischemium	NNP
2399	16405	16414	Reduction	reduction	NNP
2400	16415	16419	with	with	IN
2401	16420	16430	Aggressive	aggressive	NNP
2402	16431	16442	Cholesterol	cholesterol	NNP
2403	16451	16459	Lowering	lower	NNP
2405	16461	16464	LDL	ldl	NNP
2407	16467	16470	low	low	JJ
2408	16471	16478	density	density	NN
2409	16479	16490	lipoprotein	lipoprotein	NN
2411	16492	16494	RR	rr	NNP
2413	16497	16505	relative	relative	JJ
2414	16514	16518	risk	risk	NN
2416	16520	16522	CI	cus	NNP
2418	16525	16535	confidence	confidence	NN
2419	16536	16544	interval	interval	NN
2421	16546	16549	HDL	hdl	NNP
2423	16552	16556	high	high	JJ
2424	16557	16564	density	density	NN
2425	16573	16584	lipoprotein	lipoprotein	NN
2427	16586	16590	PTCA	ptca	NNP
2429	16593	16605	percutaneous	percutaneous	JJ
2430	16606	16618	transluminal	transluminal	NN
2431	16619	16627	coronary	coronary	JJ
2432	16636	16647	angioplasty	angioplasty	NN
2434	16649	16653	CABG	cabg	NNP
2436	16656	16664	coronary	coronary	JJ
2437	16665	16671	artery	artery	NN
2438	16672	16678	bypass	bypass	NN
2439	16679	16684	graft	graft	NN
2441	16686	16689	ECG	ecg	NNP
2443	16700	16717	electrocardiogram	electrocardiogram	NN
2445	16719	16721	A-	a-	NNP
2446	16721	16722	2	2	CD
2450	16727	16736	Aggrastat	aggrastat	NNP
2451	16737	16739	to	to	TO
2452	16740	16745	Zocor	zocor	NNP
2454	16747	16750	ACS	ac	NNP
2456	16753	16758	acute	acute	JJ
2457	16767	16775	coronary	coronary	JJ
2458	16776	16784	syndrome	syndrome	NN
2460	16786	16791	PROVE	prove	NNP
2461	16792	16794	IT	it	PRP
2463	16797	16808	Pravastatin	pravastatin	NNP
2464	16809	16811	or	or	CC
2465	16812	16824	Atorvastatin	atorvastatin	NNP
2466	16833	16843	Evaluation	evaluation	NNP
2467	16844	16847	and	and	CC
2468	16848	16857	Infection	infection	NNP
2469	16858	16865	Therapy	therapy	NNP
